Equities

Ajooni Biotech Ltd

AJOONI:NSI

Ajooni Biotech Ltd

Actions
Consumer Staples Food Producers
  • Price (INR)7.41
  • Today's Change0.06 / 0.82%
  • Shares traded468.05k
  • 1 Year change+71.52%
  • Beta1.4976
Data delayed at least 15 minutes, as of Nov 14 2024 09:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Ajooni Biotech Ltd grew revenues 7.55% from 744.88m to 801.15m while net income improved 92.17% from 11.25m to 21.61m.
Gross margin12.72%
Net profit margin2.62%
Operating margin1.94%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, Ajooni Biotech Ltd increased its cash reserves by 38.44%, or 1.19m. Cash Flow from Investing totalled 76.37m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 39.52m for operations while cash used for financing totalled 35.66m.
Cash flow per share0.2771
Price/Cash flow per share41.04
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Ajooni Biotech Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items increased 94.73%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)18.73
EPS (TTM) vs
TTM 1 year ago
31.80
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.